沸腾！暴涨近170%！中国，创造历史！

Core Viewpoint - The article highlights the significant rise of Chinese innovative drugs in the market, exemplified by the explosive debut of Zhonghui Biopharma-B, which saw a surge of nearly 160% on its first trading day, reflecting a broader trend of growth in the innovative drug sector in China [1][2][6]. Group 1: Zhonghui Biopharma-B Performance - Zhonghui Biopharma-B's stock price increased by 169.7% on its debut, closing with a nearly 160% gain [1][2]. - The company set a lower limit price of HKD 12.9 per share, raising a net amount of HKD 383 million [6]. - The public offering was oversubscribed by 4006.64 times, freezing HKD 210 billion in capital, making it the most oversubscribed biotech stock in Hong Kong this year [6]. Group 2: Growth of Innovative Drugs in China - The share of China's innovative drug BD (business development) transactions in the global market has increased from 10.8% in 2015 to an estimated 52.5% as of August 8, 2023 [9]. - The market size of innovative drugs in China reached CNY 679 billion in 2022, with projections to exceed CNY 1 trillion by 2026 and reach CNY 1.12 trillion by 2027 [9]. - The proportion of innovative drugs in the Chinese pharmaceutical market was 41% in 2022, expected to rise to 50% by 2026 and 51% by 2027 [9]. Group 3: Policy Support for Innovation - The National Healthcare Security Administration (NHSA) has held five meetings focused on supporting innovative drugs and medical devices, emphasizing a complete chain from research and development to payment [10]. - The NHSA's stance is to support genuine innovation while rejecting pseudo-innovation, which is expected to accelerate the global presence of Chinese innovative drugs and benefit patients [10].